In this issue:
Real-world CLL in Australia & NZ
Pre-clinical EZH2 + DOT1L inhibition in B-cell lymphoma
MURANO: final analysis of fixedduration venetoclax-rituximab in R/R CLL
Three molecular subtypes of CD30+ PTCL
FOLL12: prognostic utility of interim PET in follicular lymphoma
Pre-clinical data of a novel menin-KMT2A inhibitor in AML
Outcomes with CAR T-cell therapy in extranodal R/R DLBCL
Transformation to DLBCL in HL & indolent B-NHL
Next-generation BTK inhibitors in highrisk R/R CLL
Hypothetical treatment sequences for R/R T-cell & NK-cell lymphomas
Please login below to download this issue (PDF)